
Derek Brand
13K posts

Derek Brand
@echo_nyc
Have spent 15+ yrs fostering a better ecosystem for life science entrepreneurship in NYC. Now Dir. Strategic Partnerships @Columbia. Tweets and opinions my own


📢 M&A News: $GRTX to Merge w/ Obsidian Therapeutics Deal Terms » All-stock merger; combined company to operate as Obsidian Therapeutics » Concurrent $350M PIPE financing » Pro forma ownership: Obsidian ~53.2% | PIPE ~45.0% | Galera ~1.8% Lead Asset » OBX-115 (engineered autologous TIL therapy) » Indications: advanced melanoma + NSCLC » Stage: Ph2 melanoma | Ph1 NSCLC Clinical Signal » Designed with regulatable mbIL15 » May avoid high-dose IL-2 & support outpatient admin. » Built from minimally invasive core needle biopsy tissue Strategic Fit » Creates a solid tumor-focused engineered TIL company » Funded through key 2027 clinical milestones Timeline » NSCLC Ph1 data: 1H 2027 » Melanoma registration-enabling topline data: YE 2027 » Expected close: Q3 2026

@RobertFreundLaw That said the brother just found a loophole and used it. The real villian is facebook for allowing fake scams moreso in medical field on thier platform

I really did not want to be writing this morning. But this issue is too important. It’s been said that the last thing the weather person should do before going on the air is look out the window. The _day before_ @eringriffith profiled Medvi in @nytimes as the AI company of the future, the FDA approved Lilly’s new oral medication: orforglipron. *Not tirzepatide.* In fact, it’s not even a peptide. It’s the first non-peptide, small-molecule oral GLP-1 receptor agonist. Lilly owns tirzepatide. They invented it. If you could put tirzepatide in a pill, Lilly would do it. They would desperately want to. Instead, they spent millions and nearly eight years licensing a completely different kind of molecule, because oral tirzepatide is a biological impossibility. Tirzepatide is a 39-amino-acid, 4,813-dalton peptide. Your gut does not distinguish it from a piece of chicken. SNAC, the absorption enhancer that barely gets oral semaglutide to 1% bioavailability, is compound-specific. It failed with liraglutide, another GLP-1 peptide, and has no demonstrated mechanism for tirzepatide. There is no published human study of oral tirzepatide. There is no plausible mechanism. Medvi sells it starting at $279 a month. A RICO class action against its supply chain partners has already called the product modern-day snake oil. Lilly’s own strategy is the best witness. We can hear the lawyers now: “So doctor, what was your assumption on why Lilly was not pursuing oral tirzepatide despite that in not doing so they would instead pursue an entire entirely different type of molecule and possibly create market confusion with their new entrant?” The Times profile actually described an accountability architecture whose impact in part is that no single entity owns the patient and process. Medvi handles marketing. CareValidate provides the clinical workflow. OpenLoop provides prescribers and pharmacy fulfillment. The marketing layer can say the doctors make the decisions. The doctor platform can say the brand controls the messaging. The prescribers say the pharmacy fills what’s ordered. Everyone can point at everyone else. That structure explains a lot of the financials. Medvi reported a 16.2% net margin. Hims, with 2,442 employees selling the same drug categories, reported 5.5%. The 10.7-point spread represents in part everything Medvi may not pay for: extensive clinical oversight, advanced adverse event monitoring, satisfactory regulatory compliance, sound quality systems. The Times says they verified Medvi’s revenue. They did not seem to verify or note many other aspects. Six weeks before the profile ran, the FDA had issued Warning Letter #721455 for misbranding compounded GLP-1s. OpenLoop had disclosed a data breach: a threat actor claimed access to 1.6 million patient records, and multiple class actions were filed. The company’s ad network included fabricated physician personas, “Professor Albust Dongledore,” “Dr. Tuckr Carlzyn MD,” running over 5,000 Meta ads alongside a website disclaimer that these individuals “may be actors or AI portraying doctors.” The Times told the story of a man who used AI to build a billion-dollar company alone. The article was really a transcript of a Silicon Valley fever dream. A byproduct of regulatory lag and consumer desperation A billion dollars in pharmaceutical transactions running through an organization with no one seeming to care if a product can survive contact with the human stomach better than a chicken nugget.

Medvi—the first AI-enabled one-person unicorn—looks to be fraudulent. Incredible.


We used AI to predict the failure of a Phase 3 trial before the results were announced. Today, we're publishing 10 more predictions for the future. Thread 🧵



We used AI to predict the failure of a Phase 3 trial before the results were announced. Today, we're publishing 10 more predictions for the future. Thread 🧵

We believe that superhuman clinical trial forecasting is the critical bottleneck to curing all diseases. AI may compress a century of biological discovery into a decade, but if we don’t fix the broken clinical trial ecosystem, very few of those discoveries will make it to patients.

Sound and thoughtful advice from @DGlaucomflecken in my recent article on @BakerInstitute website (our policy think thank @RiceUniversity) I’ve proposed an alternative or parallel for young physicians and med students, it’s a bit out there and still half-baked bakerinstitute.org/research/reaff…

GLP-1 drugs are the ultimate validation of the techno-solutionist approach to society's most challenging problems. The obesity crisis seemed liked it would just get worse and worse forever. Scolding from public health officials didn't work. Proposals to completely overhaul our food systems were dead on arrival. Instead, we invented a weekly shot (based on Gila monster venom!) that fixes obesity directly. And now, thanks to the economic incentives in our biomedical industry, we have follow-on drugs that will be cheaper, even more effective, and easier to administer (by taking a pill instead of a shot). Policymakers should be focused on figuring out how we can get more breakthrough drugs like GLP-1s (and faster). They also should think hard about which slopulist ideas might inadvertently kill the goose that lays the golden eggs.







Doesn’t take into account that there is value to redesigning homes and other spaces so humans have more and better living space Just like warehouses were redesigned to optimize speed/storage and access. Homes, offices and other spaces can be redesigned Just because a humanoid can do the job, it doesn’t mean it’s the optimal robot for the job and space utilization Why wouldn’t you use a smaller, less expensive, easier to maintain robot that has an environment it was designed for ?







